コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 um disorder and 49.7% (95% CI 48.1-51.3) for bipolar affective disorder.
2 Lithium is a first-line therapy for bipolar affective disorder.
3 (95% CI, 1.6-4.5) times more likely to have bipolar affective disorder.
4 (95% CI, 2.7-20.6) times more likely to have bipolar affective disorder.
5 ived neurotrophic factor in the aetiology of bipolar affective disorder.
6 s being overrepresented in the patients with bipolar affective disorder.
7 may help define more homogeneous subtypes of bipolar affective disorder.
8 ctive disorder (N=26 380), of which 1928 had bipolar affective disorder.
9 everity and course, is a familial feature of bipolar affective disorder.
10 some neuropsychiatric conditions, including bipolar affective disorder.
11 ociated gene expression in schizophrenia and bipolar affective disorder.
12 re effective mood-stabilizing treatments for bipolar affective disorder.
13 es with exclusively maternal transmission of bipolar affective disorder.
14 ts and lymphocytes of euthymic patients with bipolar affective disorder.
15 ion of lithium and in the pathophysiology of bipolar affective disorder.
16 ng are associated with functional decline in bipolar affective disorder.
17 cludes schizophrenia as well as unipolar and bipolar affective disorders.
18 is relation is present for both unipolar and bipolar affective disorders.
19 rated for men and women and for unipolar and bipolar affective disorders.
20 of foreign residence had increased IRRs for bipolar affective disorder, affective disorders, persona
21 typing was carried out in 1099 patients with bipolar affective disorder and 1152 healthy comparator i
22 and lymphocytes of 44 euthymic patients with bipolar affective disorder and 27 matched comparison sub
23 f the standard antimanic treatments used for bipolar affective disorder and 38% of the treatments use
24 nd D21S171, a region which includes loci for bipolar affective disorder and a recessive form of deafn
25 set including 67 males and 113 females with bipolar affective disorder and a similar number of match
26 ty at illness onset is a familial feature of bipolar affective disorder and is associated with import
28 alence of a diagnosis of SMI (schizophrenia, bipolar affective disorder and other psychoses, and othe
30 nosis, implicating dopamine dysregulation in bipolar affective disorder and schizophrenia, in line wi
32 familial spastic paraplegia, schizophrenia, bipolar affective disorder and spinocerebellar ataxia ty
33 gene for schizophrenia, was associated with bipolar affective disorder and tested this hypothesis us
34 previous reports of high Gs alpha levels in bipolar affective disorder and, furthermore, suggest tha
36 in three or more generations, an absence of bipolar affective disorder, and a single progenitor sour
37 chiatric disorders, including schizophrenia, bipolar affective disorder, and borderline personality d
38 ng schizophrenia, major depressive disorder, bipolar affective disorder, and obsessive compulsive dis
40 are likely to contain genes contributing to bipolar affective disorder are also relevant to schizoph
43 thesis that lithium's therapeutic effects in bipolar affective disorder are mediated by alterations i
46 usly, we demonstrated evidence of linkage to bipolar affective disorder (BP) in a single large, multi
49 ), have been implicated in susceptibility to bipolar affective disorder (BP) through genome-wide asso
51 clarify the issue of genetic linkage between bipolar affective disorder (BPAD) and chromosome 18q, co
56 tics, and to have comorbid depression, mania/bipolar affective disorder (BPAD), hypertension, central
60 pletion may be the way that lithium works in bipolar affective disorder, but others have suggested th
61 and RFLP at the monoamine oxidase A locus in bipolar affective disorder cases and controls in the UK
62 hospitalization with nonaffective psychosis, bipolar affective disorder, depressive disorder, eating
66 s, a significant proportion of patients with bipolar affective disorder experience frequent relapses.
67 rate of lithium monotherapy for treatment of bipolar affective disorder (from 84% to 43%) and schizoa
68 the actual treatment of schizoaffective and bipolar affective disorders had changed in light of rece
69 , and SAP102 in subjects with schizophrenia, bipolar affective disorder I, and a comparison group.
72 bipolar affective disorder, suggesting that bipolar affective disorder in the Old Order Amish is inh
75 cifically designed for relapse prevention in bipolar affective disorder is a useful tool in conjuncti
79 peutic efficacy in manic-depressive illness (bipolar affective disorder) is the inositol depletion hy
80 chizophrenia, schizoaffective disorders, and bipolar affective disorders) is well described, but litt
84 polygenic diseases, including schizophrenia, bipolar affective disorder, non-insulin-dependent diabet
85 the apparent excess maternal transmission of bipolar affective disorder observed in some families.
89 f dementia, hereditary ataxia, Parkinsonism, bipolar affective disorder, schizophrenia and autism.
90 pecifically designed to prevent relapses for bipolar affective disorder showed encouraging results wh
91 onsidered a good candidate to investigate in bipolar affective disorder since this enzyme plays an im
92 rs and impulsivity), DRD3 (schizophrenia and bipolar affective disorder), SLC6A3 (susceptibility to c
93 6, 13 and 15 harbour susceptibility loci for bipolar affective disorder, suggesting that bipolar affe
94 confirm or refute previous reports that link bipolar affective disorder to polymorphic DNA markers at
95 s (average age = 34 +/- 16.5) diagnosed with Bipolar Affective Disorder to three patient groups all d
96 cation of candidate genes that predispose to bipolar affective disorder, to the completion of the seq
97 idual with an atypical movement disorder and bipolar affective disorder type II contains 46 triplets,
99 ene may play a role in the susceptibility to bipolar affective disorder, which underscores a potentia